Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So

Sales of Novartis' Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug's sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.

Heartbeat

Entresto is Novartis AG's key pipeline growth driver, but has had very slow uptake commercially, falling far below early expectations thanks to US market access barriers by payers. Novartis is now confident those hurdles are starting to melt away, prompting the diversified Swiss group to predict that prescription sales of the first-in-class ARNI therapy will triple over the coming year, as the group's sales force is now fully in place and reimbursement coverage in the US is more comprehensive.

Entresto, which combines the neprilysin inhibitor sacubitril with the angiotensin receptor blocker valsartan, accumulated full-year sales of $170m, below the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.